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Abstract
Introduction: Genetic manipulation of human embryonic stem cells (hESC) has been limited by their general
resistance to common methods used to introduce exogenous DNA or RNA. Efficient and high throughput
transfection of nucleic acids into hESC would be a valuable experimental tool to manipulate these cells for
research and clinical applications.
Methods: We investigated the ability of two commercially available electroporation systems, the Nucleofection®
96-well Shuttle® System from Lonza and the Neon™ Transfection System from Invitrogen to efficiently transfect
hESC. Transfection efficiency was measured by flow cytometry for the expression of the green fluorescent protein
and the viability of the transfected cells was determined by an ATP catalyzed luciferase reaction. The transfected
cells were also analyzed by flow cytometry for common markers of pluripotency.
Results: Both systems are capable of transfecting hESC at high efficiencies with little loss of cell viability. However,
the reproducibility and the ease of scaling for high throughput applications led us to perform more
comprehensive tests on the Nucleofection® 96-well Shuttle® System. We demonstrate that this method yields a
large fraction of transiently transfected cells with minimal loss of cell viability and pluripotency, producing protein
expression from plasmid vectors in several different hESC lines. The method scales to a 96-well plate with similar
transfection efficiencies at the start and end of the plate. We also investigated the efficiency with which stable
transfectants can be generated and recovered under antibiotic selection. Finally, we found that this method is
effective in the delivery of short synthetic RNA oligonucleotides (siRNA) into hESC for knockdown of translation
activity via RNA interference.
Conclusions: Our results indicate that these electroporation methods provide a reliable, efficient, and high-
throughput approach to the genetic manipulation of hESC.
Introduction
Human embryonic stem cells (hESC) are unique in their
ability to continuously self-renew while maintaining the
ability to differentiate into any cell in the adult body [1].
These characteristics give hESC the potential to be use-
ful in many different aspects of basic and clinical
research, including use as an ex vivo source for cellular
transplantation; production of cells for screening drug
candidates and assessing toxicity; and as an in vitro sys-
tem for modeling human development and disease.
However, the difficulty in producing genetically modified
hESC lines has hindered the development of some of
the most promising applications of hESC research
(reviewed in [2]). Without the ability to easily and effi-
ciently produce genetically modified cell lines, tools
such as reporter cell lines, differentiation strategies
based on the expression of certain growth factors, and
the isolation of specific populations based on marker
expression, will continue to limit the applications of
hESC research.
The most common strategy for introducing exogenous
nucleic acids into traditional, cultured cells is chemical
transfection. In this process, DNA is introduced into the
cells via liposomes or polycationic polymers (reviewed
in [3]). While this process is relatively inexpensive and
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major disadvantages. The first is that while many differ-
ent chemical transfection strategies have been attempted
to genetically modify hESC, the resulting efficiencies
have generally been very poor, often significantly less
than 1% (reviewed in [4]). An additional problem is that
even when the exogenous DNA is successfully intro-
duced into the cell, integration into the genome is poor,
and when it does occur in hESC, the exogenous gene is
often silenced, making isolation of stable transfectant
cell lines inefficient [5,6]. The low efficiency of transfec-
tion combined with the inefficient integration of the
construct into the genome makes the average efficiency
for generating stable transfectant clones in hESC around
1i n1 0
5 [5].
The bulk of successful genetic modification of hESC
has been done with lentiviral vectors (reviewed in [4]).
Lentiviral vectors are advantageous in several ways,
most important is their ability to integrate into the cel-
lular genome to produce stably expressing cell lines [7].
Lentiviral vectors have been shown to transduce many
cell types (including primary and non-dividing cells) at
high efficiencies and have been successfully used to
transduce hESC [8]. Unfortunately, the use of these vec-
tors has two major disadvantages. First, vector con-
structs larger than 11 kb package poorly, reducing the
efficiency of transduction and effectively limiting the
size of DNA that can be transferred [9]. The other dis-
advantage is the introduction of insertional mutagenesis.
Since these vectors integrate randomly, they have the
potential to activate oncogenes or inactivate tumor sup-
pressor genes in the transduced cells, therefore raising
safety concerns for potential clinical applications [10].
A third strategy for obtaining genetically modified cells
is electroporation. In this method, DNA enters cells after
an electrical current induces pore formation in the
plasma membrane. While a disadvantage of this techni-
que is reduced cell survival, electroporation has been suc-
cessful in hESC [11-13]. As with chemical transfections,
electroporation is not limited with respect to the size of
DNA elements that can be inserted into the cells. More-
over electroporation is highly versatile in that it can be
used to introduce other biological molecules such as exo-
genous proteins, mRNA or siRNA [14-18]. However, in
most applications, electroporation has been difficult to
scale for high-throughput usage.
Here we demonstrate that high throughput electropora-
tion with either of two systems, the Nucleofection® 96-
well Shuttle® System (Lonza AG, Cologne, Germany) or
the Neon System (Invitrogen, Carlsbad, CA, USA), can
efficiently deliver exogenous DNA into H9 human ESC,
and that the viability of the cells after transfection
remains high. These systems were chosen because they
might conceivably provide high-throughput applications–
the Shuttle using a 96-well plate with well-by-well trans-
fection and the Neon with convenient pipet tip-based
transfection. We found that both instruments provide
suitable transfections in hESC but that the Shuttle system
had more consistent results for high throughput applica-
tions so we chose it for further investigation. To deter-
mine whether the methods developed will be generally
suitable for hESC lines, we transfected several additional
lines and found no significant differences in transfection
efficiency or cell viability. We also demonstrate that
siRNA oligonucleotides can be efficiently transfected to
knock down protein expression.
As is the case with chemical transfections, DNA intro-
duced by the Shuttle System iso n l yr a r e l yi n t e g r a t e d
into the genome. However, the high throughput capabil-
ity of the Shuttle System allows the generation of large
numbers of viable transfectants, increasing the chance
that successful genomic integration can be recovered, as
demonstrated by the generation of a stable cell line
expressing red fluorescent protein (RFP). Although we
made no attempt to directly compare promoters and
antibiotic resistance markers, the process of generating
stable lines allowed us to make some conclusions about
the most effective promoter/resistance marker combina-
tions. As reported by others, we also noticed that two of
the most widely used viral drivers, CMV (cytomegalo-
virus immediate-early promoter) and SV40 (simian
virus-40 early promoter/origin region) are less likely to
confer stable expression in hESC [19,20].
Our study demonstrates that electroporation can be
used in a high-throughput manner to produce either
transient or stable transfectants in hESC with good via-
bility. This will to be valuable for a variety of studies
using hESC.
Materials and methods
Cell culture
Undifferentiated hESC (H9 [1], K306 [21], RNJ8 [22], and
RNJ9 [22]) were cultured in the feeder-free system
described by Ludwig and coworkers [23]. Briefly, cells
were passaged every seven days at a splitting ratio of 1:6
to 1:10, so that the resulting cultures were 80 to 90%
confluent on the day of passage. To passage, cells were
loosened from the culture substrate with 1 U/mL Dispase
( B DB i o s c i e n c e s ,S a nJ o s e ,C A ,U S A )a n dw a s h e dw i t h
DMEM/F12 medium, then gently scraped to completely
remove the colonies from the substrate and break them
into pieces. These pieces were transferred to new culture
wells pre-coated with hESC-qualified Matrigel (BD Bios-
ciences) and grown in mTeSR medium (StemCell Tech-
nologies, Vancouver, Canada). Starting 24 hours after
passaging, the medium was replenished daily.
Moore et al. Stem Cell Research & Therapy 2010, 1:23
http://stemcellres.com/content/1/3/23
Page 2 of 10Plasmid vectors
The vectors pEGFP-C, pRNAT-U6.1, and pTracer-BSD
were purchased from Clontech (Mountain View, CA,
USA), Genscript (Pistcataway, NJ, USA) and Invitrogen,
respectively. pPGK-Puro was constructed by Peter Laird
in the lab of R. Jaenisch [24]. pBM14 was constructed
by Barbara Mitta in the lab of M. Fussenegger [25] and
modified by insertion of a dsRed2 gene (details available
upon request). pCMV-BSD was constructed by M. Bren-
neman (details available upon request).
DNA electroporation with the Nucleofection® 96-well
Shuttle® System
Undifferentiated hESC were washed twice with PBS and
detached from the substrate by five minutes of incuba-
tion with Accutase (StemCell Technologies) at 37°C.
The detached cells were then dissociated by addition of
2 ml/well of mTeSR medium followed by gentle pipet-
ting. The cells were pelleted by centrifugation at 800 ×
G for three minutes and resuspended to a density of
10 × 10
6 cells/ml in H9 Human ES Cell Nucleofector
solution with the supplied supplement added (Lonza).
For each electroporation, 400 ng of the plasmid vector
pMaxGFP® (Lonza) in a volume of 2 μl was placed in
one well of a 96-well microcuvette plate (Lonza). A
total of 20 μl of cell suspension (200,000 cells) was
added to the well and pipetted to mix. Electroporation
was done using program 96-CB-150 on the Shuttle Sys-
tem. After electroporation, the contents of each micro-
cuvette well were dispersed as rapidly as possible with
80 μl of pre-equilibrated mTeSR media, then transferred
to one well of a matrigel-coated 96-well plate. Transfec-
tions carried out with the Nucleofection shuttle system
and compared to the Neon Transfection System were
prepared as described above except that one million
cells were used for each electroporation and the cells
were plated on matrigel-coated 24-well plates after
electroporation.
Neon™ transfection
Undifferentiated hESC were prepared for transfection as
described above but after dissociation cells were resus-
pended in 8 μl of Neon Resuspension Buffer R for every
one million cells. For each electroporation, cells and
2 μl of pMaxGFP (200 ng/μl, Lonza) were aliquoted into
a sterile microcentrifuge tube. A Neon Tip was inserted
into the Neon Pipette and the cell-DNA mixture was
aspirated into the tip avoiding air bubbles. The Neon
Pipette was then inserted into the Neon Tube contain-
ing 3 ml of Neon Electrolytic Buffer E in the Neon Pip-
ette Station. Cells were pulsed once with a voltage of
1,400 and a width of 20. After the pulse, cells were
quickly transferred into a matrigel-coated culture plate
containing pre-equilibrated mTeSR media.
SiRNA electroporation
Transfections were done as described above with the
exception that siRNA targeting green fluorescent protein
(GFP) (Lonza) was added to the transfection mixture at
levels of 200, 300 or 600 ng.
Twenty-four hours after transfection, the cells were
washed twice with PBS and removed from the culture
dish using Accutase (StemCell Technologies). Cells were
then resuspended in 250 μl BSA/PBS/Azide buffer as
described by Moore et al. [4]. Samples analyzed for
SSEA4 expression were blocked for 15 minutes in
DMEM/F12 (Invitrogen) containing 10% defined FBS
(Hyclone, Logan, UT, USA) followed by incubation with
phycoerythrin-labeled antibody to SSEA4 (R&D Systems,
Minneapolis, MN, USA, catalog # FAB1435P) for 30 min-
utes. After washing with DMEM/F12, cells were resus-
pended in 250 μl BSA/PBS/Azide buffer. All samples
were analyzed on a FACSCalibur flow cytometer (Becton
Dickinson, San Jose, CA, USA), and the software pro-
gram CellQuest, (Becton Dickinson, San Jose, CA, USA)
was used for data acquisition and analysis. All values are
reported as mean ± standard error of the mean.
Viability
To determine the percentage of viable cells after trans-
fection, the Vialight Kit from Lonza was used according
to the manufacturer’s protocol. This kit utilizes the ATP
present in live cells in a luciferase-catalyzed reaction to
produce light, which is measured and correlated to the
number of live cells present. Briefly, 24 hours post-
transfection, cells were lysed in 50 μl of cell lysis
solution. After incubation for 15 minutes at room tem-
perature, the cell lysates were transferred to a lumin-
ometer plate and mixed with 100 μlA M RP L U S
reagent. After two minutes of incubation at room tem-
perature in the dark, the plate was read on a lumin-
ometer. All values are reported as mean ± standard
error of the mean for replicate samples.
Immunofluorescence
Twenty-four hours post-transfection, cells in the 96-well
plates were fixed with 4% paraformaldehyde at room
temperature for 15 minutes, then permeabilized and
blocked in 4% normal goat serum with 0.1% Triton
X-100. Primary antibodies used were Oct4 (Millipore,
Billerica, MA, USA, MAB4401 at 0.5 μg/ml) and SSEA 4
(Millipore, MAB4304 at 1.0 μg/ml). After washing with
PBS, the cells were incubated with AlexaFluor conjugated
secondary antibodies (Invitrogen/Molecular Probes) at
1:500 and visualized by fluorescence microscopy.
Generation of stable transfectant lines
To generate stable transfectants, H9 or RNJ9 hESC cells
were grown and handled as described above for
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fications. After dissociation with Accutase, cells were
resuspended to two-fold higher density, so that 400,000
cells were loaded into each well of the 96-well micro-
cuvette together with 400 ng of linear or circular plas-
mid DNA. Immediately after electroporation, the cells
from each well of the microcuvette plate were dispersed
with 80 μl of mTeSR medium, then transferred to a sin-
gle matrigel-coated well of a six-well culture tray con-
taining pre-warmed mTeSR medium. Medium was
replaced 48 hours after transfection and again at
72 hours. At 96 hours after transfection, medium was
replaced and selective antibiotic (puromycin, blasticidin,
geneticin/G418 or hygromycin) was added, at concentra-
tions determined previously through kill curves. Med-
ium and selective antibiotic were replenished daily at
first, then less frequently as non-resistant cells were
cleared from the culture. Individual colonies of resistant
cells were allowed to reach 3 to 4 mm diameter, then
transferred to smaller wells for initial expansion. Trans-
fer was done by gently scraping a colony off the culture
substrate, followed by incubation with a small volume of
Accutase in a microfuge tube to dissociate the colony to
a suspension of single cells, then replating to a single
well of a 96- or 48-well tray prepared with matrigel and
mTeSR medium.
Statistics
Statistical significance was determined using a Student’s
t-test with paired equal variance and a two-tailed distri-
bution. P-values less than 0.05 were considered
significant.
Results
Efficient and high viability electroporation of H9 hESC
Two leading electroporation systems were tested for
transfection efficiency and viability. In the initial tests,
the Lonza Nucleofection® 96-well Shuttle® System was
compared with the Invitrogen Neon™ Transfection
System since both systems required small volumes, few
cells, and could conceivably be scaled for high-through-
put screening. In both systems, a DNA vector (pMax-
GFP) supplied with the Lonza Nucleofection kit and
previously shown to be suitable for protocol optimiza-
tion due to its high expression level and low toxicity
was used. For the comparison of the two systems, trans-
fections were done on a single population of cells. In
each case, a single cell suspension of 1 million undiffer-
entiated H9 hESC was mixed with 400 ng of the
pMax-GFP DNA and electroporated. Although the
Neon system had a higher mean transfection efficiency
(36.2 ± 10.3% vs. 21.2 ± 0.8%), and the viability of the
cells was similar 24 hours after transfection, variability
between multiple samples was higher when using the
Neon (Figure 1a). In order to determine any differences
in the timing of transgene expression between the two
systems, GFP expression was visualized by fluorescence
microscopy every hour after transfection for six hours.
Using both systems, GFP could be detected as little as
one hour after transfection (not shown). While both sys-
tems were effective for hESC cultures, we chose to con-
tinue with the Shuttle System due to the more uniform
transfection rates, similar viabilities, similar expression
rates, but clearly simpler capability for performing high-
throughput transfection when compared with the Neon
system.
More through testing of the Shuttle System was per-
formed to characterize its usefulness and reproducibility.
This time 200,000 cells were mixed with 400 ng pMax-
GFP and electroporated. GFP-expressing cells were
visualized by fluorescence microscopy after six hours
(Figure 1b). As a control, an equal number of cells
mixed with vector DNA but not electroporated were
also plated, and these had no visible GFP expression. At
24 hours post-transfection, pMax-GFP transfected
(referred to as transfected cells) and cells mixed with
DNA but not electroporated (control cells) were ana-
lyzed by FACS. GFP expression was detectable in 74.2 ±
1.4% of the transfected cells while the control cells had
no significant GFP expression (P <0 . 0 0 1 )( F i g u r e1 c ) .
There is a large difference in transfection efficiency seen
in Figure 1a and 1c but we believe this is due to the
density of the cells before transfection. Our experiments
suggest that there is an optimal density for transfection
and this is further covered in the discussion. In order to
determine the percentage of viable cells after transfec-
tion, the Vialight Plus Kit was used to measure ATP
levels in both the transfected and control cells. The per-
centage of cells that remained viable after pMax-GFP
transfection was 73.5 ± 3.2%, while the viability of the
control cells was 91.6 ± 2.7% (Figure 1c). Although
transfection significantly reduced cell viability
(P < 0.001), the remaining viable cells are sufficient for
most purposes and once transfected can easily be
expanded (data not shown).
The ability to transfect hESC in a high throughput
manner is an important first step in optimizing proto-
cols for small molecule screens. In order to determine
the suitability of the Shuttle System for this purpose, we
compared the survival rate and transfection efficiency of
cells electroporated in the first and last wells of a 96-
well microcuvette shuttle pl a t e .A ss e e ni nF i g u r e1 d
there was no statistically significant difference between
the viability of cells electroporated in the first and last
columns of a 96-well plate (61.8 ± 0.04% vs. 61.9 ±
0.03%, P > 0.05), however a small decrease in the effi-
ciency of transfection was observed (41.0 ± 1.2% vs.
36.5 ± 1.3%, P < 0.05). Despite the small decrease in
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this technique for high throughput screens.
Transfected H9 hESC retain expression of pluripotent
markers
The ability of hESC to maintain their pluripotency after
transfection is required for developing successful proto-
cols. To determine whether H9 cells continued to
express pluripotent markers after transfection, the
expression of Oct4 and SSEA4, two commonly used
markers, was determined by immunofluorescence. As
seen in Figure 2a, b, large numbers of electroporated
cells (green in Figure 2) continued to be Oct4-positive
(red in Figure 2a) and SSEA4-positive (red in Figure 2b)
24 hours after transfection, independent of their GFP
expression. To quantitatively determine if the majority
of cells retained pluripotency markers after electropora-
tion, the percentage of SSEA4 positive cells were quanti-
fied by FACS. As seen in Figure 2c, 24 hours after
electroporation, 74.4 ± 4.3% of electroporated cells
expressed SSEA4, while 72.8 ± 4.4% of non-electropo-
rated, control cells expressed SSEA4 (P > 0.5), demon-
strating no difference in pluripotency between
transfected and non-transfected cells. In addition, 79.9 ±
4.7% of cells that were expressing GFP 24 hours after
transfection also expressed SSEA4
+, which is similar to
the rate found in the entire culture. The SSEA4-positive
cells can potentially be separated from the differentiated
cells by flow sorting or manual picking of colonies,
a l l o w i n gap u r ec u l t u r eo ft r a n sfected, pluripotent cells
to be propagated.
Transfection of siRNA
To determine whether the 96-well Shuttle® System was
also capable of efficiently delivering siRNAs for gene
knock-down, the pMax-GFP plasmid was co-transfected
with siRNA oligonucleotides that targeted the GFP tran-
script. The amount of siRNA needed to suppress GFP
expression effectively was determined by titrating var-
ious amounts of siRNA with the pMax-GFP vector
(siRNA to pMax-GFP mass ratios of 3:1, 1.5:1 and
0.75:1). Fluorescence microscopy showed that GFP
expression was visibly reduced when a three-fold excess
of GFP-targeting siRNA was co-transfected (Figure 3a).
FACS analysis showed that an siRNA to DNA ratio of
3:1 reduced the percentage of cells expressing GFP by
71.75% when compared to cells transfected in the
absence of siRNAs (P < 0.01) (Figure 3b). siRNA to
DNA ratios of 1.5:1 and 0.75:1 also reduced the percen-
tage of GFP-positive cells by 31.7 (P < 0.01) and 18.0%
(P < 0.05), respectively (Figure 3b). This demonstrates
that the system can also be used for the transfection of
siRNAs to knockdown protein expression.
Transfection efficiency in multiple hESC lines
To ensure that the transfection efficiency seen with H9
was not specific to that cell line, two additional hESC
lines were tested. These lines were RNJ8 [22] and the
HS306 hESC line [21]. Figure 4 shows the percentage of
cells that were GFP positive by FACS analysis 24 hours
after transfection (as described above). Transfection of
the RNJ8 and HS306 lines resulted in 55.8 ± 4.8% and
53.6 ± 2.6% GFP-expressing cells, respectively, demon-
strating that this method of transfection is suitable for
Figure 1 Transfection of H9 is efficient and the resulting cells
have a high viability. (a) Comparison of the Neon and Shuttle®
Systems. Both systems can result in the efficient transfection of
hESC. While the Neon system had a higher transfection efficiency, it
also had increased variability between multiple transfections (36.2 ±
10.3% vs. 21.2 ± 0.8%). b) Transfected H9, phase contrast image (left
panel) and GFP fluorescent image (right panel). (c) Quantification of
Viability and Efficiency. FACS analysis demonstrates that after
electroporation 73.5 ± 3.2% of the cells remain viable (compared to
the 91.6 ± 2.7% viable in control reactions; P < 0.001) and that the
transfection efficiency is 74.2 ± 1.4% (P < 0.001). (d) Viability and
Transfection Efficiency in High Through-put Formats. All 96 wells of
a shuttle plate were electroporated and the viability and efficiency
of the first and last columns were compared. FACS analysis
demonstrates that there is no change in viability between the first
and last columns (61.8 ± 0.04% vs. 61.9 ± 0.03%, P > 0.05), however
there is a small but significant decrease in transfection efficiency
(41.0 ± 1.2% vs. 36.5 ± 1.3%, P < 0.05).
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ent laboratories.
Generation of stable transfectant H9 cell lines
Isolation of stable transfectant clones requires some
means to separate them from the larger fraction of cells
that have not integrated vector DNA into their chromo-
somes. The simplest and most widely used method is
antibiotic selection, which requires that a marker gene
for antibiotic resistance be included in the vector DNA.
Four different antibiotic resistance markers were tested in
H9 cells: Puro (puromycin N-acetyltransferase), BSD
(blasticidin-S deaminase), Hyg (hygromycin-B phospho-
transferase) and Neo (neomycin phosphotransferase)
(Table 1). These four markers are included in many com-
mercially available mammalian expression vectors under
the transcriptional control of various viral or mammalian
promoter/enhancer sequences. To investigate the ability
of the Shuttle System transfections to produce stable
Figure 2 Transfected H9 express markers of pluripotency. (a)
Fluorescence image of GFP transfected cells (green) that express
Oct4 (red). (b) Fluorescence image of GFP transfected cells (green)
that express SSEA4 (red). (c) FACS analysis for markers of
pluripotency 24 hours after electroporation demonstrate that
control and transfected cells expressed similar amounts of SSEA4
(blue bars; 74.4 ± 4.3% vs. 72.8 ± 4.4%; P > 0.5). In addition, of the
GFP expressing cells 79.9 ± 4.7% also express SSEA4 (green bars).
Figure 3 Co-transfection with siRNA can suppress GFP
expression. (a) Co-transfection of a siRNA that targets GFP at a 3:1
mass ratio to pMax-GFP results in reduced GFP expression (left
panel). Transfection with pMax-GFP only (right panel). (b)
Quantification of GFP knock-down by FACS analysis demonstrates
that siRNA to vector DNA ratios of 3:1,1.5:1 and 0.75:1 result in GFP
reductions of 71.75%, 31.7% and 18.0% (P < 0.01, 0.01 and 0.05,
respectively).
Figure 4 Multiple hESC lines are transfected efficiently.I n
addition to the H9 cell line, two hESC cell lines, RNJ8 and HS306,
were also efficiently transfected, with resulting percentages of GFP-
expressing cells greater than 50%.
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SV40 promoters were tested, in addition to markers dri-
ven by promoter/enhancer units from two mammalian
genes; murine phosphoglycerate kinase (PGK) and
human elongation factor 1-alpha (EF1a) (Table 1). Work-
ing doses for selection in H9 cells were established
through a series of kill curves with puromycin, blastici-
din-S, hygromycin-B and the neomycin analog geneticin
(G418). The lowest dose that would completely kill an
approximately 80% confluent well (24-well tray) of non-
transfected H9 cells over five days or less was taken as a
starting point for transfection trials.
In order to maximize the recovery of stable transfec-
tants, we found that the density of initial plating and the
timing of selective drug application is crucial in hESC
cells, since these cells apparently require close cell-to-
cell contacts, and generally will not survive as a dis-
persed monolayer of separated cells. Our transient
transfection experiments showed that GFP can be
expressed in as little as one hour and this is presumably
true for antibiotic resistance proteins as well. But if the
selective drug is applied too early, stably transfected
cells may become isolated and suffer from reduced sur-
vival rates as the non-resistant cells surrounding them
die, despite their antibiotic resistance. To avoid this pro-
blem, we delayed the addition of selective antibiotics to
the growth medium until 96 hours after transfection. In
this way, resistant cells are afforded time to undergo
multiple rounds of cell division, thereby forming a
micro-colony of resistant cells before selection begins.
Doing so required that the hESC cells be plated after
transfection at a density high enough to allow the cells
to reestablish cell-to-cell contacts and resume growth,
but low enough to allow four days of growth without
forming a confluent culture of fused colonies. To
achieve this, the cells were generally re-plated after elec-
troporation at a density of 400,000 cells/well in a six-
well culture tray. Plating at densities of 300,000 cells/
well or less resulted in very sharply reduced cell attach-
ment and survival. Plating at densities of 600,000 cells/
well or higher tended to result in cultures so dense after
four days that it became difficult to clear the back-
ground of nonresistant cells and recover cleanly isolated
colonies of resistant cells. Optimum plating densities for
selection may prove to be somewhat different for hESC
lines.
The frequency with which stable transfectant clones
could be recovered varied among the selective drugs and
vectors tested (Table 1). The best recoveries, 30 or more
colonies per well, were achieved using puromycin selec-
tion, with a vector in which the Puro gene was driven by
the mouse PGK promoter/enhancer. Blasticidin selection
was also effective, with the best results from a vector
with a BSD gene driven by the human EF1a promoter/
enhancer. Although a vector with BSD driven by a CMV
promoter/enhancer also yielded stable transfectants, the
frequency was much lower. Geneticin (G418) selection
allowed recovery of stable clones as well, with somewhat
higher frequencies from a PGK-Neo vector than from an
SV40-Neo vector. We were not successful in recovering
stable transfectants by hygromycin selection, despite
repeated attempts over a range of drug concentrations.
Whether this reflects poor expression from the SV40-dri-
ven Hyg gene tested, low activity of the hygromycin-B
phosphotransferase protein, or other factors in H9 cells is
unclear.
In order to investigate the long term expression of
multiple transgenes and their effect on pluripotency,
RNJ9 stable transfectants expressing dsRed2 driven by
the EF1a promoter and neomycin resistance driven by
the PGK promoter were also isolated and maintained
for more than 10 passages. During this time the cells
maintained their RFP expression and immunofluores-
cence for Oct4 and SSEA4 confirmed their pluripo-
tency (Figure 5a, b). This demonstrates that the
Shuttle System is suitable for long term transgene
expression, as well as bi-cistronic vector transfection,
which is necessary for many applications such as
reporter lines and lines harboring lineage specific
genetic modifications.
Table 1 Efficiency of stable clone generation based on resistance markers and their promoters
Vector Resistance marker Transcriptional control Selective drug (dose) Frequency of stable integrants
5
pPGK-Puro Puro PGK
1 Puromycin (0.5 μg/ml) >8 × 10
-5
pTracer-BSD BSD (GFP fusion) EF1a
2 Blasticidin-S (2.0 μg/ml) 4.9 × 10
-5
pCMV-BSD BSD CMV
3 Blasticidin-S (2.0 μg/ml) 6.3 × 10
-6
pBM14 Neo PGK
1 Geneticin/G418 (50 μg/ml) 6.0 × 10
-6
pEGFP-C3 Neo SV40
4 Geneticin/G418 (50 μg/ml) 6.3 × 10
-6
pRNAT-U6.1 (GFP) Hyg SV40
4 Hygromycin-B (10 to 100 μg/ml) <1.0 × 10
-6 (none recovered)
1Murine phosphoglycerate kinase promoter/enhancer.
2Human elongation factor 1-alpha promoter/enhancer.
3Cytomegalovirus immediate-early promoter/enhancer.
4Simian virus-40 promoter/origin region.
5Values shown represent means of two to six experiments.
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The ability to genetically modify hESC with a high effi-
ciency will provide new tools for understanding basic
human development and tracking cells transplanted into
animal models. In order to identify a method that can
be used to efficiently electroporate hESC and be easily
scaled for high-throughput applications, we tested the
Nucleofection® 96-well Shuttle® System from Lonza and
the Neon™ Transfection system from Invitrogen. Both
systems require low cell numbers, express transgenes in
as little as one hour and are capable of efficiently trans-
fecting hESC with a high viability. However, the higher
reproducibility of the Shuttle® System coupled with its
ability to perform up to 96 individual transfections in
batch mode led us to pursue the Shuttle over the Neon
system.
Here we establish that the 96-well Shuttle® System can
be used to deliver DNA, as well as siRNA, and can gener-
ate genetically modified hESC lines. The greatest advan-
tage of this system is the high transfection efficiency that
can be achieved with a small number of cells in a high
through-put manner. Although other groups have used
electroporation to transfect hESC, the reported protocols
required one to two million cells per transfection and
were performed one transfection at a time [11,13,26,27].
Since the culture of hESC is time consuming and expen-
sive it is advantageous that the number of cells necessary
to achieve these high transfection efficiencies was only
200,000 per well and the viability of the transfected cells
was often above 50%. These efficiencies were not cell line
specific, as we were able to routinely transfect several
independently derived hESC lines at efficiencies of at least
50% and sometimes as high as 70%. Interestingly, there
seemed to be a correlation between initial density of the
cells used for transfection and the transfection efficiency -
the denser the cells were immediately before transfection,
the less efficient the transfection. This may be due to the
stress placed on cells that become too dense suggesting
that highest transfection efficiencies are achieved when the
cells are in the exponential growth phase. Since the Shut-
tle® System uses a 96-well format, this method could be
readily scaled up to perform multiple transfections in par-
allel for multiple replicates of multiple groups, or for
screening large numbers of plasmids or siRNAs. To this
Figure 5 Stable hESC cell line expressing red fluorescent protein. RNJ9 cells transfected with EF1a-RFP/PGK-Neo were selected with 50 μg/ml
G418 for two weeks after transfection and then grown for 10 passages. (a) Fluorescence images of dapi (blue), SSEA4 (green; in fixed cells SSEA4
staining appears punctuate due to the disruption of the cell membrane by paraformaldehyde, and RFP (red). (b) Fluorescence images of dapi
(blue), Oct4 (green), and RFP (red).
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nificantly decreased over an entire 96-well plate and that
the transfection efficiency was only slightly reduced. Simi-
larly, siRNA electroporation proved to be effective, at least
on a gene carried by a co-transfected plasmid.
In order for genetically modified hESC to be usable in
most applications, the modified cells must retain their
pluripotency. We used immunofluorescence and FACS
analysis to demonstrate the presence of pluripotency mar-
kers in the modified cells with, Oct4 and SSEA4. No statis-
tically significant decreases in markers were observed
between transfected and non-transfected cells, demon-
strating that this method is suitable for expressing trans-
genes while likely maintaining pluripotency in both short
term (transient transfection) and long term (stable trans-
fection) experiments. It is important to note that more
extensive characterization, such as karyotyping and tera-
toma formation of newly generated stable lines, would
need to be done before the line could be formally consid-
ered to be pluripotent. Using this system we have also
investigated the efficiency at which several different anti-
biotic selection cassettes and the promoters driving them
can be used to derive stable cell lines. The majority of
commonly used selection cassettes utilize either the CMV
or SV40 promoters to drive their antibiotic resistance
genes. However, several groups have reported difficulty in
obtaining stable expression with these promoters, presum-
ably due to gene silencing in both the undifferentiated
hESC and hESC-derived differentiated cells [19,20].
Although we were able to use both the CMV and SV40
promoters to obtain stable lines, these occurred at a fre-
quency which was at least 10-fold less than that of the
EF1a and PGK promoters. Our data suggest that EF1a
and PGK promoters are most efficient for the generation
of stable lines and demonstrates that resulting lines can
maintained in a pluripotent state for at least 10 passages.
Conclusions
We have demonstrated that electroporation is a suitable
method for reliable, efficient transfection of hESC and
that the Lonza Nucleofection® 96-well Shuttle® System
can be scaled to high throughput methods while main-
taining pluripotency. In addition to traditional DNA
vector transfection, this method can also be used to
transfect small RNA molecules to facilitate the knock-
down of target genes. With these methods, the protocols
necessary for a better understanding of stem cell biology
can be generated, accelerating the application of clinical
translation with these cells.
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